rituximab

B lymphocyte-typing for prediction of clinical response to rituximab

Introduction: The prediction of therapeutic response to rituximab in rheumatoid arthritis is desirable. We evaluated whether analysis of B lymphocyte subsets by flow cytometry would be useful to identify non-responders to rituximab ahead of time. Methods: Fifty-two patients with active rheumatoid arthritis despite therapy with TNF-inhibitors were included in the national rituximab registry. DAS28 was determined before and [...]

Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label

marco.marques 2016-10-16T12:02:14+01:00 2011-12-1|Categories: Divulgação|Tags: adalimumab, etanercept, Infection rate, infliximab, rituximab, Sjögren syndrome, systemic lupus erythematosus, vasculitis|

Introduction: The purpose of this observational study was to analyze the rates, characteristics and associated risk factors of severe infections in patients with systemic autoimmune diseases (SAD) who were treated off-label with biological agents in daily practice. Methods: The BIOGEAS registry is an ongoing Spanish prospective cohort study investigating the long-term safety and efficacy of the off-label use of [...]

Núcleo de Estudos de Doenças Auto-imunes

B lymphocyte-typing for prediction of clinical response to rituximab

Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label

rituximab